Valisure

Valisure operates as an independent laboratory providing chemical analysis and quality certification of pharmaceutical drugs and consumer healthcare products. It has played a key role in uncovering contamination issues in widely used medications such as ranitidine/Zantac and valsartan, leading to regulatory actions including recalls. The company partners with health systems, government agencies, manufacturers, and other stakeholders to improve transparency and safety in the healthcare supply chain. It has no clinical results or pipeline programs; instead, its impact includes published studies on drug quality discrepancies and successful advocacy resulting in regulatory changes. Recent milestones include opening a new state-of-the-art laboratory facility in New Haven in October 2024, strategic partnerships such as with Picket Pharmaceuticals for injectable drug certification, leadership transition to CEO Chip Phillips in February 2024, and funding from AlleyCorp/Connecticut Innovations. Key clients include Kaiser Permanente and US Armed Forces. Valisure is accredited to ISO/IEC 17025 standards for analytical testing. The company formerly operated an online pharmacy that dispensed only batch-tested medications but divested this business line in 2021 to focus on enterprise services.